Effectiveness of injectable extended-release naltrexone vs daily buprenorphine–naloxone for opioid dependence: a randomized clinical noninferiority trial.

Key points from summary and commentary A novel study testing the relative effectiveness of injections of extended-release naltrexone and a daily combination of oral buprenorphine hydrochloride and naloxone hydrochloride for maintaining abstinence from heroin and other opioids. Treatment with extended-release naltrexone was found no less effective than buprenorphine–naloxone in terms of retaining patients in treatment, reducing the number of days of injecting and craving for opioids, and reducing the use of heroin, and other illicit drugs. The authors concluded that maintaining short-term abstinence with extended-release naltrexone should be considered an “equal” medication-assisted treatment alternative to buprenorphine-naloxone for opioid-dependent individual